Fundraising Fox
Galectin Therapeutics
NASDAQ: GALTNorcross, US · Nevada corporation
Find your way into Galectin Therapeutics
1 person in our graph can introduce you to the Galectin Therapeutics team.
Sign up to see every warm intro you have to Galectin Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Galectin Therapeutics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Galectin Therapeutics develops galectin-3 inhibitor therapies, including its lead carbohydrate-based drug belapectin (GR-MD-02), for patients with chronic liver disease and cancer. Its lead program targets MASH (non-alcoholic steatohepatitis) cirrhosis and fibrosis.
Founders & leadership
JC
James C CzirrFounder
JW
Jack W CallicuttCFOJack W Callicutt is an Executive Officer and Director at Galectin Therapeutics, which develops galectin-3 inhibitor therapies for chronic liver disease and cancer. He has financial and operational expertise in the biotech industry, with background in SEC reporting, corporate finance, and strategic planning.
PG
Peter G TraberExecutivePeter G. Traber is an Executive Officer and Director at Galectin Therapeutics, which develops galectin-3 inhibitor therapies for chronic liver disease and cancer. He has background experience in biotechnology, pharmaceutical industry, healthcare, and biomedical research.
JL
Joel LewisPresident and Chief Executive Officer, Director
Board
KD
Kevin D FreemanBoard director
GS
Gilbert S OmennBoard director
AR
Arthur R GreenbergBoard director
MR
Marc RubinBoard director
JG
John G. MauldinBoard director
GF
Gilbert F AmelioBoard director
SG
Steven G. PrelackBoard director
Funding
SEC filings, press & company announcements$4.5M disclosed across 2 of 7 rounds · 1900–2019
- Undisclosed amountRights OfferingMay 2019Source ↗
▶$3MraisedJan 2017 · 5 investors · PharmaceuticalsRule 506(b)
▶$3MraisedJan 2017 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kevin D FreemanDirector
- Gilbert S OmennDirector
- Harold H. ShlevinExecutive Officer
- Theodore ZuconniDirector
- Steven G. PrelackDirector
- Gilbert F AmelioDirector
- Marc RubinDirector
- James C CzirrDirector
- John G. MauldinDirector
- Peter G TraberExecutive Officer, Director
- Jack W CallicuttExecutive Officer
- Arthur R GreenbergDirector
- Offering amount
- $10M
- Amount sold
- $3M
- First sale
- Dec 2016
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1.5MraisedSep 2016 · 1 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedSep 2016 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Marc RubinDirector
- Jack W CallicuttExecutive Officer, Director
- James C CzirrDirector
- Gilbert S OmennDirector
- Peter G TraberExecutive Officer, Director
- Steven G. PrelackDirector
- John G. MauldinDirector
- Arthur R GreenbergDirector
- Kevin D FreemanDirector
- Gilbert F AmelioDirector
- Offering amount
- $12M
- Amount sold
- $1.5M
- First sale
- Sep 2016
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶Undisclosed amountofferedDec 2015 · 6 investors · PharmaceuticalsRule 506(b)
▶Undisclosed amountofferedDec 2015 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kevin D FreemanDirector
- Jack W CallicuttExecutive Officer, Director
- James C CzirrExecutive Officer, Director
- Gilbert S OmennDirector
- Arthur R GreenbergDirector
- Peter G TraberExecutive Officer, Director
- Marc RubinDirector
- John G. MauldinDirector
- Gilbert F AmelioDirector
- Steven G. PrelackDirector
- Sales commissions
- $588.6K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Nov 2015
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies working in the same space as Galectin Therapeutics.
In the news
Frequently asked questions
- What does Galectin Therapeutics do?
- Galectin Therapeutics develops galectin-3 inhibitor therapies, including its lead carbohydrate-based drug belapectin (GR-MD-02), for patients with chronic liver disease and cancer. Its lead program targets MASH (non-alcoholic steatohepatitis) cirrhosis and fibrosis.
- Who founded Galectin Therapeutics?
- Galectin Therapeutics was founded by James C Czirr.
- How much funding has Galectin Therapeutics raised?
- Galectin Therapeutics has disclosed $4.5M raised across 2 of its 7 known rounds.
- Where is Galectin Therapeutics headquartered?
- Galectin Therapeutics is headquartered in Norcross, US.